Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rhea N Coler

Showing results (51-60 of 132) with videos related to

Pageof 14
Sort By:
Vaccine|November 17, 2015
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adultsMarilia Santini-Oliveira, Rhea N Coler, Juçara Parra, et al.
Vaccines|May 26, 2018
Enhanced Anti-<i>Mycobacterium tuberculosis</i> Immunity over Time with Combined Drug and Immunotherapy TreatmentSasha E Larsen, Susan L Baldwin, Mark T Orr, et al.
Virulence|May 2, 2022
Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against <i>Mycobacterium avium</i> infection but is ineffective as an adjunct to antibiotic treatment in chronic diseaseJu Mi Lee, Jiyun Park, Steven G Reed, et al.
Vaccine|September 6, 2002
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvantYasir A W Skeiky, Rhea N Coler, Mark Brannon, et al.
Scientific Reports|October 31, 2019
Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse modelKee Woong Kwon, Ara Lee, Sasha E Larsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 2, 2013
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsSusan L Baldwin, Lance K Ching, Samuel O Pine, et al.
The Journal of Infectious Diseases|August 15, 2012
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatmentRhea N Coler, Sylvie Bertholet, Samuel O Pine, et al.
Vaccine|June 17, 2020
Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunityTres Cookenham, Kathleen G Lanzer, Emily Gage, et al.
Plos One|July 26, 2012
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140Mauricio A Arias, Griet A Van Roey, John S Tregoning, et al.
Vaccine|November 7, 2015
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacyMark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Pageof 14

Showing results (51-60 of 132) with videos related to

Sort By:
Pageof 14
Vaccine|November 17, 2015
Schistosomiasis vaccine candidate Sm14/GLA-SE: Phase 1 safety and immunogenicity clinical trial in healthy, male adultsMarilia Santini-Oliveira, Rhea N Coler, Juçara Parra, et al.
Vaccines|May 26, 2018
Enhanced Anti-<i>Mycobacterium tuberculosis</i> Immunity over Time with Combined Drug and Immunotherapy TreatmentSasha E Larsen, Susan L Baldwin, Mark T Orr, et al.
Virulence|May 2, 2022
Vaccination inducing durable and robust antigen-specific Th1/Th17 immune responses contributes to prophylactic protection against <i>Mycobacterium avium</i> infection but is ineffective as an adjunct to antibiotic treatment in chronic diseaseJu Mi Lee, Jiyun Park, Steven G Reed, et al.
Vaccine|September 6, 2002
Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvantYasir A W Skeiky, Rhea N Coler, Mark Brannon, et al.
Scientific Reports|October 31, 2019
Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse modelKee Woong Kwon, Ara Lee, Sasha E Larsen, et al.
Journal of Immunology (Baltimore, Md. : 1950)|August 2, 2013
Protection against tuberculosis with homologous or heterologous protein/vector vaccine approaches is not dependent on CD8+ T cellsSusan L Baldwin, Lance K Ching, Samuel O Pine, et al.
The Journal of Infectious Diseases|August 15, 2012
Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatmentRhea N Coler, Sylvie Bertholet, Samuel O Pine, et al.
Vaccine|June 17, 2020
Vaccination of aged mice with adjuvanted recombinant influenza nucleoprotein enhances protective immunityTres Cookenham, Kathleen G Lanzer, Emily Gage, et al.
Plos One|July 26, 2012
Glucopyranosyl Lipid Adjuvant (GLA), a Synthetic TLR4 agonist, promotes potent systemic and mucosal responses to intranasal immunization with HIVgp140Mauricio A Arias, Griet A Van Roey, John S Tregoning, et al.
Vaccine|November 7, 2015
Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacyMark T Orr, Elyse A Beebe, Thomas E Hudson, et al.
Pageof 14